LACEY ROACH: Open Payments
NPI 1730848201 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,408 in 143 payments from 15 companies in 2025. Trend: 2023 $59 · 2024 $4,028 · 2025 $3,408
Food & beverage: $3,408
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $1,020 |
| AstraZeneca Pharmaceuticals LP | 18 | $553 |
| UCB, Inc. | 18 | $482 |
| Amgen Inc. | 26 | $382 |
| GENZYME CORPORATION | 2 | $255 |
| Janssen Biotech, Inc. | 6 | $223 |
| E.R. Squibb & Sons, L.L.C. | 9 | $179 |
| Novartis Pharmaceuticals Corporation | 7 | $136 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| Fresenius Kabi USA, LLC | 2 | $38 |
Products named: RINVOQ, SAPHNELO, Bimzelx, TREMFYA, EVENITY, ORENCIA, SKYRIZI, COSENTYX.
Industry payments across OK — which companies pay providers there.
